Literature DB >> 28560484

A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis.

Ganesh Pantham1, Anthony Post2, Deepak Venkat2, Douglas Einstadter3, Kevin D Mullen4.   

Abstract

BACKGROUND AND AIMS: Overt hepatic encephalopathy (HE) is a major cause of significant morbidity and mortality in patients with liver cirrhosis. We examined the frequency and profile of the precipitating factors resulting in hospitalizations for overt HE.
METHODS: We conducted both retrospective and prospective studies to identify clinical precipitants of overt HE in patients with cirrhosis. The retrospective study patients were hospitalized at a large urban safety-net hospital, and the prospective study included the patients admitted at a liver transplant center.
RESULTS: There were a total of 149 patients with cirrhosis and overt HE (91 males, mean age 55.3 ± 8.6 years) in the retrospective group and 45 patients (27 males, mean age 58.3 ± 8.2 years) in the prospective group of the study. The average MELD score was 16 ± 6.8 in the retrospective group and 22.7 ± 7.2 in the prospective group. Dehydration (46-76%), acute kidney injury (32-76%), lactulose nonadherence (about 50%), constipation (about 40%), and infections (20-42%) were the most frequently identified precipitants for hospitalization in retrospective and prospective groups. Multiple precipitants were identified in 60 (40.3%) patients in the retrospective group and 34 (76%) patients in the prospective group.
CONCLUSIONS: Multiple concurrent precipitating factors were identified in the majority of patients with overt HE requiring hospitalization. Dehydration due to various causes was the most common precipitant of overt HE, followed by acute kidney injury (AKI), constipation, and infections. Prevention of dehydration, AKI, and constipation by close outpatient monitoring may be an effective measure to prevent hospitalization for overt HE in patients with cirrhosis.

Entities:  

Keywords:  Cirrhosis; MELD score; Overt hepatic encephalopathy

Mesh:

Substances:

Year:  2017        PMID: 28560484     DOI: 10.1007/s10620-017-4630-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

Review 1.  Theories of the pathogenesis of hepatic encephalopathy.

Authors:  E Anthony Jones; Kevin D Mullen
Journal:  Clin Liver Dis       Date:  2012-02       Impact factor: 6.126

Review 2.  Astrocytic-ammonia interactions in hepatic encephalopathy.

Authors:  M D Norenberg
Journal:  Semin Liver Dis       Date:  1996-08       Impact factor: 6.115

3.  Precipitating factors and the outcome of hepatic encephalopathy in liver cirrhosis.

Authors:  Khalid Mumtaz; Umair Syed Ahmed; Shahab Abid; Noshaba Baig; Saeed Hamid; Wasim Jafri
Journal:  J Coll Physicians Surg Pak       Date:  2010-08       Impact factor: 0.711

Review 4.  Review article: the burden of hepatic encephalopathy.

Authors:  F F Poordad
Journal:  Aliment Pharmacol Ther       Date:  2007-02       Impact factor: 8.171

Review 5.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

6.  Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis.

Authors:  Samuel H Sigal; Carmen M Stanca; Nickolas Kontorinis; Carol Bodian; Elizabeth Ryan
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

7.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

8.  Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients.

Authors:  J S Bajaj; A J Sanyal; D Bell; H Gilles; D M Heuman
Journal:  Aliment Pharmacol Ther       Date:  2010-02-05       Impact factor: 8.171

9.  Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis.

Authors:  Mónica Guevara; M E Baccaro; Aldo Torre; Beatriz Gómez-Ansón; José Ríos; Ferrán Torres; Lorena Rami; Gemma C Monté-Rubio; Marta Martín-Llahí; Vicente Arroyo; Pere Ginès
Journal:  Am J Gastroenterol       Date:  2009-06       Impact factor: 10.864

10.  A study on the position and etiology of infection in cirrhotic patients: A potential precipitating factor contributing to hepatic encephalopathy.

Authors:  Qiu-Ming Wang; Qing Ji; Zhi-Jun Duan; Ming Zhang; Qing-Yong Chang
Journal:  Exp Ther Med       Date:  2013-06-03       Impact factor: 2.447

View more
  12 in total

Review 1.  Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy.

Authors:  Lise L Gluud; Rebecca Jeyaraj; Marsha Y Morgan
Journal:  J Clin Exp Hepatol       Date:  2019-02-15

2.  Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection.

Authors:  Paul Feuerstadt; Simon J Hong; Lawrence J Brandt
Journal:  Dig Dis Sci       Date:  2019-08-22       Impact factor: 3.199

3.  Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.

Authors:  Harry D Zacharias; Antony P Zacharias; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

4.  Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Puneeta Tandon; Florence Wong; Patrick S Kamath; Scott W Biggins; Guadalupe Garcia-Tsao; Jennifer Lai; Michael B Fallon; Paul J Thuluvath; Hugo E Vargas; Benedict Maliakkal; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Aliment Pharmacol Ther       Date:  2019-04-29       Impact factor: 8.171

5.  Practical Issues in the Management of Overt Hepatic Encephalopathy.

Authors:  Ganesh Pantham; Kevin D Mullen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-11

6.  Assessment of the spectrum of hepatic encephalopathy: A multicenter study.

Authors:  Bradley Reuter; Kara Walter; Julien Bissonnette; Michael D Leise; Jennifer Lai; Puneeta Tandon; Patrick S Kamath; Scott W Biggins; Christopher F Rose; James B Wade; Jasmohan S Bajaj
Journal:  Liver Transpl       Date:  2018-05       Impact factor: 5.799

7.  The Psychometric Hepatic Encephalopathy Syndrome score does not correlate with blood ammonia, endotoxins or markers of inflammation in patients with cirrhosis.

Authors:  Nina Kimer; Lise Lotte Gluud; Julie Steen Pedersen; Juliette Tavenier; Søren Møller; Flemming Bendtsen
Journal:  Transl Gastroenterol Hepatol       Date:  2021-01-05

8.  Unexpected clinical outcomes following the implementation of a standardised order set for hepatic encephalopathy.

Authors:  Mandip Kc; Andrew P J Olson; Qi Wang; Nicholas Lim
Journal:  BMJ Open Gastroenterol       Date:  2021-04

Review 9.  Hepatic encephalopathy: current challenges and future prospects.

Authors:  Mirashini Swaminathan; Mark Alexander Ellul; Timothy Js Cross
Journal:  Hepat Med       Date:  2018-03-22

10.  A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy.

Authors:  Aisha Vadhariya; Hua Chen; Omar Serna; Hani Zamil; Susan M Abughosh
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.